Targeting Oncogenic miRNAs in NSCLC: Therapeutic Strategies and Emerging Approaches

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) is a major global cause of cancer mortality, particularly in advanced stages.
• MicroRNAs (miRNAs) are crucial regulators in NSCLC, functioning as tumor suppressors or oncogenes (oncomiRs) and influencing cancer progression and drug resistance.

Purpose of the Study:

• To review therapeutic strategies targeting oncogenic miRNAs in NSCLC.
• To focus on the potential of small molecule inhibitors (SMIs) for NSCLC treatment.
• To assess the current research landscape, challenges, and opportunities for miRNA-based therapies in NSCLC.

Main Methods:

• Literature review of current research on therapeutic strategies for oncogenic miRNAs in NSCLC.
• Analysis of small molecule inhibitors (SMIs), miRNA mimics, and antisense oligonucleotides.
• Discussion of pharmacokinetic advantages and bioavailability of SMIs compared to RNA-based therapies.

Main Results:

• Oncogenic miRNAs significantly contribute to NSCLC pathogenesis and drug resistance.
• Small molecule inhibitors (SMIs) present potential advantages in pharmacokinetics and oral bioavailability for miRNA targeting.
• Direct clinical evidence for SMIs targeting oncogenic miRNAs in NSCLC is currently limited.

Conclusions:

• miRNA-based therapies hold promise for NSCLC treatment.
• Further research is essential to develop effective and selective small molecule inhibitors for clinical use in NSCLC.
• Overcoming challenges in clinical translation is key for advancing miRNA-targeted therapies in NSCLC.